Northern Trust Corp Raises Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Northern Trust Corp grew its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 9.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 608,392 shares of the biotechnology company's stock after purchasing an additional 52,574 shares during the quarter. Northern Trust Corp owned about 0.96% of Blueprint Medicines worth $53,064,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. The Manufacturers Life Insurance Company lifted its position in Blueprint Medicines by 17.7% during the 4th quarter. The Manufacturers Life Insurance Company now owns 176,484 shares of the biotechnology company's stock worth $15,393,000 after acquiring an additional 26,488 shares during the last quarter. Tudor Investment Corp ET AL boosted its position in shares of Blueprint Medicines by 208.0% in the fourth quarter. Tudor Investment Corp ET AL now owns 8,100 shares of the biotechnology company's stock valued at $706,000 after acquiring an additional 15,600 shares during the period. Aquatic Capital Management LLC grew its stake in shares of Blueprint Medicines by 11.7% in the fourth quarter. Aquatic Capital Management LLC now owns 47,602 shares of the biotechnology company's stock worth $4,152,000 after acquiring an additional 5,002 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in Blueprint Medicines during the 4th quarter valued at $4,906,000. Finally, Virtus ETF Advisers LLC boosted its holdings in Blueprint Medicines by 22.0% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,777 shares of the biotechnology company's stock valued at $329,000 after purchasing an additional 681 shares during the period.

Blueprint Medicines Price Performance

NASDAQ:BPMC traded down $1.02 during trading hours on Friday, hitting $97.74. The company's stock had a trading volume of 621,844 shares, compared to its average volume of 780,742. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The company has a market capitalization of $6.31 billion, a P/E ratio of -90.50 and a beta of 0.83. Blueprint Medicines Co. has a twelve month low of $73.04 and a twelve month high of $121.90. The stock has a fifty day simple moving average of $88.49 and a 200-day simple moving average of $93.81.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.32). The business had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The company's revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.40 earnings per share. On average, analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. JMP Securities restated a "market outperform" rating and issued a $125.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. Wolfe Research assumed coverage on shares of Blueprint Medicines in a research note on Tuesday, March 18th. They issued an "outperform" rating for the company. StockNews.com upgraded shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research report on Friday, May 2nd. Needham & Company LLC cut their price target on shares of Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating for the company in a research note on Monday, April 28th. Finally, JPMorgan Chase & Co. upped their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $126.56.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 3,203 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the transaction, the insider now owns 18,270 shares in the company, valued at approximately $1,692,167.40. This represents a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the sale, the chief operating officer now owns 69,266 shares of the company's stock, valued at approximately $6,581,655.32. This represents a 3.18 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,503 shares of company stock valued at $1,027,931. 4.21% of the stock is currently owned by company insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.